UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000047422
Receipt number R000054080
Scientific Title Perioperative duloxetine administration reduces pain after high tibial osteotomy and non-steroidal anti-inflammatory administration
Date of disclosure of the study information 2022/04/06
Last modified on 2022/04/06 17:54:51

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Perioperative duloxetine administration reduces pain after high tibial osteotomy and non-steroidal anti-inflammatory administration

Acronym

The effect of perioperative duloxetine administration for pain reduction

Scientific Title

Perioperative duloxetine administration reduces pain after high tibial osteotomy and non-steroidal anti-inflammatory administration

Scientific Title:Acronym

The effect of perioperative duloxetine administration for pain reduction

Region

Japan


Condition

Condition

osteoarthritis

Classification by specialty

Orthopedics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To determine whether perioperative duloxetine administration reduces pain after knee surgery.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

Numeric rating scale

Key secondary outcomes

Pain catastrophizing Scale
Knee Injury and Osteoarthritis Outcome Score (KOOS)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

YES

Institution consideration


Blocking


Concealment

Pseudo-randomization


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Patients in the duloxetine group received one 20-mg capsule once daily for 1 week at 3 weeks before surgery and two 20-mg capsules once daily for 2 weeks before surgery.

Interventions/Control_2

Patients received non-steroidal anti-inflammatory drugs (NSAIDs; 60 mg) for severe pain, and three tablets per day were permitted as the maximum dose.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Osteoarthritis

Key exclusion criteria

Rheumatoid arthritis

Target sample size

80


Research contact person

Name of lead principal investigator

1st name Shuhei
Middle name
Last name Otsuki

Organization

Osaka Medical and Pharmaceutical University

Division name

Department of orthopedic surgery

Zip code

569-8686

Address

2-7 Daigakumachi Takatsuki Osaka Japan

TEL

0726831221

Email

Shuhei.otsuki@ompu.ac.jp


Public contact

Name of contact person

1st name Shuhei
Middle name
Last name Otsuki

Organization

Osaka Medical and Pharmaceutical University

Division name

Department of orthopedic surgery

Zip code

569-8686

Address

2-7 Daigakumachi Takatsuki Osaka Japan

TEL

0726831221

Homepage URL


Email

Shuhei.otsuki@ompu.ac.jp


Sponsor or person

Institute

Department of orthopedic surgery, Osaka Medical and Pharmaceutical University

Institute

Department

Personal name



Funding Source

Organization

no

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Osaka Medical and Pharmaceutical University

Address

2-7 Daigakumachi Takatsuki Osaka Japan

Tel

0726831221

Email

Shuhei.otsuki@ompu.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 04 Month 06 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

80

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 04 Month 22 Day

Date of IRB

2019 Year 07 Month 02 Day

Anticipated trial start date

2019 Year 07 Month 15 Day

Last follow-up date

2022 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2022 Year 04 Month 06 Day

Last modified on

2022 Year 04 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000054080


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name